CAMBIO DE DISCURSO : LA SECOND-LINE SCLC-ES TRAS EL FIASCO DE LA FASE III LAGOON YA MEJOR NI NOMBRARLA...CAMBIAMOS DISCURSO A MANTENIMIENTO EN FIRTS-LINE . JazzPharma TO WITHDRAW LURBINECTEDIN WITH US_FDA IN SECOND-LINE SCLC-ES.. SI NO EXISTIERA IMFORTE...AHORA MISMO PHARMAMAR ESTARÍA ANTE UNA GRAVE SITUACIÓN ... 2 DE OCTUBRE DE 2028 ... ES LA FECHA MÁS TEPMPRANA PARA LA POSIBLE ENTRADA DE GENÉRICOS .
20 enero 2010
19 enero 2010
Kill - Paff ONE , Nuevo lanzamiento de Copyr , la Filial de Zelnova ( Grupo Zeltia ) .
Copyr was established in 1961 as Compagnia del Piretro; since then our core business has always been the formulation of highly effective insecticides with superior safety profile, mainly based on pyrethrum and pyrethroids. With the increased sensitivity towards environmental protection and safety for operators and consumers, the know how acquired by Copyr in the formulation of products with active ingredients of natural origin has contributed to consolidate a position of leadership in the domestic market.
In May 2006 Copyr was aquired by Zelnova S.A. and entering the Zeltia Group.
Exitoso trasplante para tratar leucemia .
Científicos llevaron a cabo exitosamente en humanos una técnica de trasplante de células de cordón umbilical que eventualmente podría reemplazar la necesidad de encontrar donantes de médula ósea para tratar la leucemia y otros tipos de cáncer en la sangre.
...
...
18 enero 2010
Yondelis combinado con Doxorrubicina podria mejorar los resultados en STS segun ensayos que se llevan a cabo .
...Trabectedin is the only approved drug for the treatment of relapsed STS, and it is recommended by the European guidelines for the treatment of advanced or metastatic STS with particular efficacy against leiomyosarcoma and liposarcoma. In phase II clinical trials, trabectedin provided disease control and/or clinical benefit in more than 50% of patients and was accompanied by a median overall survival (OS) rate of up to 14 months. The combination of trabectedin and doxorubicin extends the OS rate to 15 months. These encouraging results support the role of trabectedin in the treatment of STS. The results of ongoing clinical trials investigating the activity of trabectedin in combination with other chemotherapeutic agents and in specific histological subtypes of STS should further define the place of this emerging agent in the management of this difficult‐to‐treat population.
.
Bryostatin 1 es un fármaco Anticancerigeno , sin embargo, se ha visto que ha dado buenos resultados para combatir el Alzheimer .
Hay quienes viven de los recuerdos y hay quienes no recuerdan lo que es vivir .
...
...
17 enero 2010
Ian Judson Clinical Medical Oncologist The latest new treatment - Trabectedin (Yondelis®) for metastatic or advanced Soft Tissue Sarcoma .
Yondelis en UK . A la luz de esta recomendación positiva, el profesor Ian Judson, catedrático de Farmacología Oncológica en la Unidad de Desarrollo Farmacéutico del Royal Marsden Hospital, aseguró que "le complace enormemente la noticia de que 'Yondelis' vaya a estar disponible para los pacientes que cumplan los requisitos clínicos, dado el beneficio prolongado que hemos observado en algunos de los pacientes tratados aquí en el Marsden".
...
J&J Y Pharma Mar han conseguido introducir el Velcade y el Yondelis respectivamente en UK , un ejemplo a seguir .
...
"Trabectedin is recommended as a treatment option for people with advanced soft tissue sarcoma if:
treatment with anthracyclines and ifosfamide has failed or
they are intolerant of or have contraindications for treatment with anthracyclines and ifosfamide and
the acquisition cost of trabectedin for treatment needed after the fifth cycle is met by the manufacturer."
...
"Trabectedin is recommended as a treatment option for people with advanced soft tissue sarcoma if:
treatment with anthracyclines and ifosfamide has failed or
they are intolerant of or have contraindications for treatment with anthracyclines and ifosfamide and
the acquisition cost of trabectedin for treatment needed after the fifth cycle is met by the manufacturer."
...
16 enero 2010
Otto , el Perro más viejo del Mundo murio a los 21 años , Padecía un Cancer de Estomago .
Otto, el perro más viejo del mundo, ha muerto a los 21 años, que equivale a 146 años según la edad de los seres humanos.
...
15 enero 2010
A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.
Departament de Neurología, Hospital Santa Creu y Sant Pau , Universidat Autónoma de Barcelona, Barcelona, Spain.
...
14 enero 2010
13 enero 2010
Suscribirse a:
Entradas (Atom)